Breath Test for Diagnosing Fungal Pneumonia
This type of fungal pneumonia is difficult to diagnose and in most cases a lung biopsy is necessary to obtain more accurate identification. However, such an invasive procedure could be difficult, and even dangerous, for debilitated patients with weakened immune systems, including organ or bone marrow transplant recipients and patients on chemotherapy.
Hence, the challenge for experts is to find a noninvasive method that can also identify the type of fungus causing pneumonia to enable timely and targeted treatment in these cases. Sophia Koo, MD, of Brigham and Women's Hospital in Boston (MA, USA), and her colleagues set out to find a unique "chemical signature" in the breath of patients being evaluated for fungal pneumonia. They prospectively collected breath samples from patients with suspected invasive fungal pneumonia from 2011 to 2013.
In their research, Dr. Koo et al. identified several compounds, or metabolites, normally produced by Aspergillus fumigatus and other fungi that can cause pneumonia. The next step was to analyse breath samples from 64 patients with suspected cases of invasive aspergillosis. This would allow the team to assess if it was possible to distinguish patients with this fungal pneumonia from patients who did not have this illness.
New Technique Detects Fungal Infection with High Accuracy
Based on the identification of these fungal compounds in the breath samples, the researchers were able to identify patients with the fungal infection with high accuracy: 94 percent sensitivity and 93 percent specificity. This means that the "breath test" was able to detect 94 percent of patients who actually had or probably had the disease, and misidentified as infected seven percent of patients who did not have the infection.
According to the hospital team, the breath collection procedure was implemented without any problem. It was well-tolerated, including by patients who had difficulty breathing or required supplemental oxygen.
"Identification of the underlying microbial etiology remains elusive in most patients with pneumonia, even with invasive diagnostic measures," Dr. Koo noted. "Our findings provide proof-of-concept that we can harness detection of species-specific metabolites to identify the precise microbial cause of pneumonia, which may guide appropriate treatment of these infections."
More work is needed to validate the findings and refine the approach before it can be considered for clinical use, the researchers said. If supported by future research, the new technique also may be used in other types of pneumonia. "We can likely also use this volatile metabolite profiling approach to identify other, more common causes of pneumonia," Dr. Koo pointed out.
Image Credit: Wikimedia Commons
Published on : Fri, 24 Oct 2014
Print as PDF
The iLA Membrane Ventilator is an extrapulmonary ventilation system which is used primarily to remove carbon dioxide. The heart pumps blood through it as it does through a natural organ. The gas exchange takes place via a plasma-tight, heparin-coated...
Get an complete overview of your POCT setup - from one dashboard Your point-of-care-testing setup probably involves many different types of devices from various manufacturers. Radiometer's AQURE point-of-care management system can give you an overview...
The HAMILTON-T1 combines for the first time the functionality of a fully featured intensive care unit ventilator with the compactness and ruggedness required for transport. This is why the HAMILTON-T1 enables you to provide optimal ventilation therapy...
Monitor vital signs of sensitive patients with reliable, smart and intuitive technology Not available in the US Sensitive patients, like neonates, require comfortable care. With transcutaneous monitoring, you can easily keep track of the oxygenation...
XENIOS AG is a medical device company with the three brands, novalung, i-cor and medos, that run on a single XENIOS platform. This platform enables next-generation therapies for lung and heart failure. No other company except XENIOS AG is offering lung...